Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
May explain nonhemodynamic ACE inhibitor benefits in LV dysfunction; leaves open clinical translation in prospective trials.
LD treatment with ACE inhibitors restored beta-adrenergic signal transduction defects independently of regression of cardiac hypertrophy. This could contribute to the effects of ACE inhibitors in patients, who are often treated with nonhypotensive doses.
No takes yet. Share an insight, caveat, or question.
Böhm et al. (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: